Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus farciminis
- Development stage
- Phase 1
- Lead developer
- STI Biotechnologie
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Lactobacillus farciminis is a species of lactic acid bacteria investigated for its probiotic properties. It is being studied for its potential to alleviate stress-induced visceral hypersensitivity, a key symptom of Irritable Bowel Syndrome (IBS). [1, 5] Research suggests its mechanism of action involves modulating the gut-brain axis, strengthening the intestinal barrier, and exerting anti-inflammatory effects. [1, 4] Specifically, it has been shown to prevent increases in colonic paracellular permeability, inhibit the phosphorylation of myosin light chain (MLC) in colonocytes, and reduce the expression of the neuronal activation marker Fos in the spinal cord and brain regions associated with stress and pain. [1, 2, 5] Some of these effects may be mediated by the release of nitric oxide (NO) in the colon. [2, 4] The developer Lallemand has sponsored clinical research into its effects. [15] Lactobacillus farciminis is also used in animal nutrition, both in livestock and companion animals, to support gut health and improve performance. [3, 7, 8]
- Brand names
- Biacton
- Other names
- L. farciminisCompanilactobacillus farciminis
02
Targets
MLCK (Myosin light chain kinase)MUC2 (Mucin-2)
Beyond the preview
Go deeper on lactobacillus farciminis.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus farciminis.